129 related articles for article (PubMed ID: 37789581)
1. Screen-positive rate in cell free DNA screening for trisomy 21.
Lüthgens K; Häbig K; Sonek J; Kagan KO
Prenat Diagn; 2023 Nov; 43(12):1536-1543. PubMed ID: 37789581
[TBL] [Abstract][Full Text] [Related]
2. Fetal fraction-based risk algorithm for non-invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell-free fetal DNA.
McKanna T; Ryan A; Krinshpun S; Kareht S; Marchand K; Grabarits C; Ali M; McElheny A; Gardiner K; LeChien K; Hsu M; Saltzman D; Stosic M; Martin K; Benn P
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):73-79. PubMed ID: 30014528
[TBL] [Abstract][Full Text] [Related]
3. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA screening for trisomy 21 in twin pregnancy: a large multicenter cohort study.
Dugoff L; Koelper NC; Chasen ST; Russo ML; Roman AS; Limaye MA; Ranzini AC; Clifford CM; Biggio JR; Subramaniam A; Seasely A; Patil AS; Weed S; Page JM; Nicholas S; Idler J; Rao RR; Crowder A; Shree R; McLennan G; Bromley B
Am J Obstet Gynecol; 2023 Oct; 229(4):435.e1-435.e7. PubMed ID: 37030426
[TBL] [Abstract][Full Text] [Related]
5. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive prenatal screening in twin pregnancies with cell-free DNA using the IONA test: a prospective multicenter study.
Khalil A; Archer R; Hutchinson V; Mousa HA; Johnstone ED; Cameron MJ; Cohen KE; Ioannou C; Kelly B; Reed K; Hulme R; Papageorghiou AT
Am J Obstet Gynecol; 2021 Jul; 225(1):79.e1-79.e13. PubMed ID: 33460583
[TBL] [Abstract][Full Text] [Related]
7. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study.
Sánchez-Durán MÁ; Bernabeu García A; Calero I; Ramis Fossas J; Illescas T; Avilés MT; Maiz N; Carreras E
BMC Pregnancy Childbirth; 2019 Aug; 19(1):274. PubMed ID: 31370808
[TBL] [Abstract][Full Text] [Related]
9. Contingent cfDNA Screening Implementation: Increasing Diagnostic Accuracy and Reducing Invasive Testing - 6 Years' Results in a Single Center.
Cubo AM; Huélamo M; Martín-Seisdedos MC; Hernández-Hernández E; Lapresa-Alcalde MV; Rodríguez-Martín MO; Doyague MJ; Sayagués JM
Fetal Diagn Ther; 2022; 49(3):103-113. PubMed ID: 35259749
[TBL] [Abstract][Full Text] [Related]
10. Effect of preexamination conditions in a centralized-testing model of non-invasive prenatal screening.
Fibke C; Giroux S; Caron A; Starks E; Parker JDK; Swanson L; Jouan L; Langlois S; Rouleau G; Rousseau F; Karsan A
Clin Chem Lab Med; 2022 Jan; 60(2):183-190. PubMed ID: 34761647
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation.
Dar P; Jacobsson B; MacPherson C; Egbert M; Malone F; Wapner RJ; Roman AS; Khalil A; Faro R; Madankumar R; Edwards L; Haeri S; Silver R; Vohra N; Hyett J; Clunie G; Demko Z; Martin K; Rabinowitz M; Flood K; Carlsson Y; Doulaveris G; Malone C; Hallingstrom M; Klugman S; Clifton R; Kao C; Hakonarson H; Norton ME
Am J Obstet Gynecol; 2022 Aug; 227(2):259.e1-259.e14. PubMed ID: 35085538
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic outcomes following a failed cell-free DNA screen: a population-based retrospective cohort study of 35,146 singleton pregnancies.
Bellai-Dussault K; Meng L; Howley H; Reszel J; Huang T; Lanes A; Walker MC; Okun N; Dougan SD; Armour CM
Am J Obstet Gynecol; 2023 Aug; 229(2):168.e1-168.e8. PubMed ID: 36627072
[TBL] [Abstract][Full Text] [Related]
13. Cell-Free DNA Analysis in Maternal Blood: Differences in Estimates between Laboratories with Different Methodologies Using a Propensity Score Approach.
Bevilacqua E; Jani JC; Letourneau A; Duiella SF; Kleinfinger P; Lohmann L; Resta S; Cos Sanchez T; Fils JF; Mirra M; Benachi A; Costa JM
Fetal Diagn Ther; 2019; 45(5):302-311. PubMed ID: 29898450
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA analysis in maternal blood: comparing genome-wide versus targeted approach as a first-line screening test.
de Wergifosse S; Bevilacqua E; Mezela I; El Haddad S; Gounongbe C; de Marchin J; Maggi V; Conotte S; Badr DA; Fils JF; Guizani M; Jani JC
J Matern Fetal Neonatal Med; 2021 Nov; 34(21):3552-3561. PubMed ID: 31722585
[TBL] [Abstract][Full Text] [Related]
15. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.
Petersen AK; Cheung SW; Smith JL; Bi W; Ward PA; Peacock S; Braxton A; Van Den Veyver IB; Breman AM
Am J Obstet Gynecol; 2017 Dec; 217(6):691.e1-691.e6. PubMed ID: 29032050
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China.
Liu Y; Liu H; He Y; Xu W; Ma Q; He Y; Lei W; Chen G; He Z; Huang J; Liu J; Liu Y; Huang Q; Yu F
Hum Genomics; 2020 Jun; 14(1):21. PubMed ID: 32503639
[TBL] [Abstract][Full Text] [Related]
17. Clinical Review of Noninvasive Prenatal Testing: Experience from 551 Pregnancies with Noninvasive Prenatal Testing-Positive Results in a Tertiary Referral Center.
Wu X; Li Y; Xie X; Su L; Cai M; Lin N; Du S; Xu L; Huang H
J Mol Diagn; 2020 Dec; 22(12):1469-1475. PubMed ID: 33069877
[TBL] [Abstract][Full Text] [Related]
18. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result.
Revello R; Sarno L; Ispas A; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jun; 47(6):698-704. PubMed ID: 26743020
[TBL] [Abstract][Full Text] [Related]
19. Assessment and Clinical Utility of a Non-Next-Generation Sequencing-Based Non-Invasive Prenatal Testing Technology.
Gormus U; Chaubey A; Shenoy S; Wong YW; Chan LY; Choo BP; Oraha L; Gousseva A; Persson F; Prensky L; Chin E; Hegde M
Curr Issues Mol Biol; 2021 Aug; 43(2):958-964. PubMed ID: 34449543
[No Abstract] [Full Text] [Related]
20. Association between low fetal fraction in cell-free DNA screening and fetal chromosomal aberrations: A systematic review and meta-analysis.
Becking EC; Schuit E; van Baar de Knegt SME; Sistermans EA; Henneman L; Bekker MN; Scheffer PG
Prenat Diagn; 2023 Jun; 43(7):838-853. PubMed ID: 37143173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
